Li Bin Form 4 SCICLONE PHARMACEUTICALS / Bin Li ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Ally Bridge LB Healthcare Master Fund Ltd

(Last) (First) (Middle)

UNIT 3002-3004,30TH FLR,GLOUCESTER TOWER

THE LANDMARK, 15 QUEEN'S ROAD CENTRAL

(Street)

HONG KONG

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SCICLONE PHARMACEUTICALS INC [ SCLN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
Former member, 10% owner group

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2017

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Ally Bridge LB Healthcare Master Fund Ltd

(Last) (First) (Middle)

UNIT 3002-3004,30TH FLR,GLOUCESTER TOWER

THE LANDMARK, 15 QUEEN'S ROAD CENTRAL

(Street)

HONG KONG

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Ally Bridge LB Management Ltd

(Last) (First) (Middle)

UNIT 3002-3004,30TH FLR,GLOUCESTER TOWER

THE LANDMARK, 15 QUEEN'S ROAD CENTRAL

(Street)

HONG KONG

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

ABG Management Ltd

(Last) (First) (Middle)

UNIT 3002-3004,30TH FLR,GLOUCESTER TOWER

THE LANDMARK,15 QUEEN'S ROAD CENTRAL

(Street)

HONG KONG

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Yu Fan

(Last) (First) (Middle)

UNIT 3002-3004,30TH FLR,GLOUCESTER TOWER

THE LANDMARK,15 QUEEN'S ROAD CENTRAL

(Street)

HONG KONG

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Li Bin

(Last) (First) (Middle)

UNIT 3002-3004,30TH FLR,GLOUCESTER TOWER

THE LANDMARK,15 QUEEN'S ROAD CENTRAL

(Street)

HONG KONG

(City) (State) (Zip)

Explanation of Responses:

Remarks:

Ally Bridge LB Healthcare Master Fund Limited (the "Master Fund") directly owns 678,077 shares of Common Stock. Ally Bridge LB Management Limited ("LB Management") owns the sole voting share of the Master Fund. Mr. Fan Yu and Mr. Bin Li are the shareholders and directors of LB Management, and Mr. Yu is the shareholder and director of ABG Management Limited. LB Management, by virtue of it being the holder of the sole voting share of the Master Fund, and each of Mr. Yu and Mr. Li, by virtue of being a shareholder and director of LB Management, may be deemed to have voting control and investment discretion over the shares held by the Master Fund. Each of LB Management, ABG Management Limited, Mr. Yu and Mr. Li disclaims beneficial ownership of such securities and this Form 4 shall not be deemed an admission that any of them is the beneficial owner of, or has any pecuniary interest in, such securities for any purposes. On February 17, 2017, ABG Management Limited delivered a notice to the other members of the Consortium ("Termination Notice") to withdraw from the Consortium, and the Consortium Agreement was thereby terminated with respect to ABG Management Limited, as described in that certain statement on Schedule 13D filed on February 17, 2017. As a result, the Reporting Persons are no longer party to any agreement, arrangement or understanding with respect to securities of the Issuer that might deem them to be in a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934. The Reporting Persons together do not beneficially own more than 10% of the outstanding shares of Common Stock.

	Ally Bridge LB Healthcare Master Fund Limited, /s/ Bin Li, Director	02/17/2017
	Ally Bridge LB Management Limited, /s/ Bin Li, Director	02/17/2017
	ABG Management Limited, /s/ Fan Yu, Director	02/17/2017
	/s/ Fan Yu	02/17/2017
	/s/ Bin Li	02/17/2017
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.